Weimob (SEHK:02013) H2 2025 Earnings call March 17, 2026 08:00 AM ET Company ParticipantsCao Yi - CFOSun Taoyong - Chairman of the Board and CEOYou Fengchun - Executive Director and PresidentConference Call ParticipantsLiao Yuan - AnalystXia Jun - AnalystOperatorThe event is for invited investors only. The audio recording transcript is for meeting for internal use by participants, not to be made public. Weimob Group has not authorized any media outlet to redistribute any content of this event. Any unauthori ...

Summary of ACADIA Pharmaceuticals Conference Call Company Overview - **Company**: ACADIA Pharmaceuticals (NasdaqGS:ACAD) - **Focus**: Development of treatments for central nervous system disorders, particularly Alzheimer's disease psychosis and Lewy body dementia psychosis Key Points Alzheimer's Disease Psychosis Program - **Next Generation Molecule**: Remlifanserin (formerly ACP-204), a 5-HT2A inverse agonist, aims to improve upon pimavanserin (NUPLAZID), the first approved treatment for Parkinson's disease psychosis [4][5] - **Goals**: - Reduce QT prolongation risk - Allow for greater dose ranging - Achieve faster time to steady state [4][5] - **Current Status**: Remlifanserin is in phase 2 trials for both Alzheimer's disease psychosis and Lewy body dementia psychosis [5] Comparison with Pimavanserin - **Pimavanserin's Efficacy**: Mixed results in indications like schizophrenia and major depressive disorder, but showed potential in Alzheimer's [9][10] - **Expectations for Remlifanserin**: Higher probability of success due to improved study design and molecule characteristics, including the ability to achieve higher exposure levels [10][11] Trial Design Improvements - **Study Design**: The new trial is community-based rather than limited to nursing homes, ensuring a more representative patient population [18] - **Endpoints**: Utilizing SAPS-H+D for better sensitivity to change compared to the previous NPI-NH scale [19] - **Powering**: The phase 2 study is powered for a moderate effect size of 0.4 with 80% power [24] Regulatory Considerations - **FDA Interaction**: The company is gathering data rigorously to address safety concerns, particularly regarding the black box warning associated with pimavanserin [26][28] - **Potential for Phase 2 as Pivotal Trial**: The phase 2 study is designed to be rigorous enough to potentially serve as a pivotal trial, depending on the outcomes [32][34] Lewy Body Dementia - **Biomarker Testing**: The study will include alpha-synuclein biomarkers to differentiate between patient subpopulations [64][65] - **Comparative Probability of Success**: There is a belief that Lewy body dementia may have a higher probability of success compared to Alzheimer's disease psychosis, although both have their merits [58][59] Other Pipeline Assets - **ACP-211**: A selectively deuterated R-ketamine for major depressive disorder (MDD) is in development, aiming for ketamine-like efficacy without sedation and dissociation [73][74] - **Phase 2 Study Goals**: To assess efficacy while ruling out unacceptable levels of sedation and dissociation [74] Upcoming Data Readouts - **Timeline**: Data readouts for the Alzheimer's disease psychosis program (remlifanserin) are expected between August and October [81][82] Additional Considerations - **Patient Compliance**: The ease of administration and safety profile are critical for patient adherence to the treatment [49][50] - **Long-term Safety**: While the phase 2 study will not definitively answer long-term cognitive impact, it will provide initial insights [56][57] This summary encapsulates the key discussions and insights from the ACADIA Pharmaceuticals conference call, focusing on their ongoing research and development efforts in treating Alzheimer's disease psychosis and Lewy body dementia.

China Literature (SEHK:00772) H2 2025 Earnings call March 17, 2026 08:00 AM ET Company ParticipantsCao Huayi - Non-executive DirectorHou Xiaonan - CEOHuang Yan - SVP and Executive DirectorJacky Xu - VP of FinanceMaggie Zhou - Head of Capital Markets and Investor RelationsNone - TranslatorConference Call ParticipantsGigi Zhou - Research AnalystJenny Yuan - Research AnalystMaggie Ye - Research AnalystXu Zhengzheng - VP and Equity AnalystOperatorGood evening, ladies and gentlemen. Welcome to China Literature's ...

Lifeway Foods (NasdaqGM:LWAY) Q4 2025 Earnings call March 17, 2026 08:00 AM ET Company ParticipantsJohn Mills - Managing Director of Investor RelationsJulie Smolyansky - CEO and PresidentJohn MillsGood morning. Welcome to Lifeway Foods' fourth quarter and full year 2025 conference call. On the call with me today is Julie Smolyansky, President and Chief Executive Officer. By now, everyone should have access to the press release that went out this morning. If you have not received the release, it is available ...

Financial Data and Key Metrics Changes - In Q4 2025, the company reported total revenue of CNY 1 billion, with a gross margin of 10.8% [5][17] - For the full year 2025, total revenue reached CNY 4 billion, down from CNY 4.5 billion in 2024, reflecting lower order volumes amid intensified market competition [17] - Adjusted net profit increased by 107.1% year-over-year to CNY 41.6 million in Q4 2025, and for the full year, adjusted net profit was nearly CNY 200 million [5][19] - The non-GAAP net margin improved to 5% from 4.5% in 2024 [16] Business Line Data and Key Metrics Changes - The share of mid to high-value delivery orders has been steadily increasing, particularly in the electronics delivery category, which saw a 17% year-over-year increase in order volume [7][8] - Cake delivery returned to growth in Q4 2025, with order volume increasing by over 5% year-over-year [8] Market Data and Key Metrics Changes - As of the end of 2025, the service network expanded to 298 cities across China, with 31 million registered riders and 120 million registered users [4][5] - Demand for high-quality delivery services remains strong, with expectations for stable order volume in 2026 compared to 2025 [25] Company Strategy and Development Direction - The company emphasizes a differentiated service experience as its core competitive advantage, focusing on operational refinement and service quality [5][15] - FlashEx is exploring low-altitude delivery and has established a dedicated logistics division for drone delivery, which has entered real-world operations [11][12] - The integration of AI technology is a key focus, with applications in customer service, operations, and R&D to enhance efficiency and service quality [13][26] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the intense competition in the on-demand delivery industry but remains confident in the company's operational foundation and service capabilities [15][20] - The company plans to continue leveraging technology and innovation to capture emerging opportunities and create long-term value [20] Other Important Information - The company held CNY 951.6 million in cash and cash equivalents as of the end of 2025 [6][19] - The introduction of AI-assisted coding tools increased development efficiency by roughly 30% compared to 2024 [13] Q&A Session Questions and Answers Question: Could you please share our fourth quarter order volume and ASP trends broken down by B2B and B2C segments? What is our outlook for order volume trends this year, and what are the key drivers? - In Q4 2025, the company fulfilled 63.2 million orders, with total fulfillment orders for the year amounting to 249.2 million. The outlook for 2026 is for stable order volume, driven by consistent demand for high-quality services [24][25] Question: How will the management strategize to embrace AI? How will this boost our efficiency? - The company is leveraging AI across various areas to enhance operational efficiency, including customer service and delivery operations. Future plans include AI agent-based interactions to simplify user experiences [26][27][28]

GDS (NasdaqGM:GDS) Q4 2025 Earnings call March 17, 2026 08:00 AM ET Company ParticipantsDaniel Newman - CFOEllie Jiang - Head of Asia Internet & SoftwareJonathan Atkin - Managing DirectorLaura Chen - Head of Investor RelationsWilliam Huang - Founder, Chairman, and CEOYang Liu - Executive DirectorConference Call ParticipantsDaley Li - VP and Equity Research AnalystGokul Hariharan - Managing Director and Senior Equity Research AnalystTimothy Zhao - Equity Research AnalystXinyi Wang - Equity Research AnalystNo ...

China Literature (SEHK:00772) H2 2025 Earnings call March 17, 2026 08:00 AM ET Company ParticipantsCao Huayi - Non-executive DirectorHou Xiaonan - CEOHuang Yan - SVP and Executive DirectorJacky Xu - VP of FinanceMaggie Zhou - Head of Capital Markets and Investor RelationsNone - TranslatorConference Call ParticipantsGigi Zhou - Research AnalystJenny Yuan - Research AnalystMaggie Ye - Research AnalystXu Zhengzheng - VP and Equity AnalystOperatorGood evening, ladies and gentlemen. Welcome to China Literature's ...

Financial Data and Key Metrics Changes - Overall revenue grew by 80.9%, reaching CNY 1.592 billion, with a gross profit (GP) margin of CNY 1.2 billion, reflecting a 100% year-over-year increase [4][30] - GP margin rate increased by 31%, reaching 75.1%, indicating a successful high-quality development strategy [4] - Adjusted profit turned positive at CNY 42 million, with positive cash flows and free cash flow reaching CNY 300 million [6][38] Business Line Data and Key Metrics Changes - Subscription revenue was CNY 900 million, showing a slight decrease of 2.3% due to historical low-margin orders and economic pressures [30][33] - Merchant Solutions revenue grew by 65.1%, reaching CNY 690 million, with a GP margin for Merchant Solutions reaching 90% [5][30] - AI-related revenue reached CNY 160 million, contributing significantly to the overall revenue and indicating a new growth engine [5][31] Market Data and Key Metrics Changes - The retail industry spending on software continued to decline, impacting the SaaS business, but the company managed to optimize its customer base [8][29] - The overall market environment remains challenging due to deflation and tight merchant budgets, but the company is adapting through strategic transformation [29][30] Company Strategy and Development Direction - The company is focusing on an "All-in AI" strategy and high-quality growth, with plans to continue expanding into local life services and verticals like pets and fitness [3][9] - The international expansion strategy aims to support Chinese enterprises in global markets, leveraging AI for marketing and operational solutions [25][64] - The company is enhancing its multi-channel marketing strategy, including partnerships with platforms like Douyin and Xiaohongshu [12][70] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving significant growth in 2026, driven by AI adoption and international expansion [40][66] - The company acknowledges the challenges posed by AI on the SaaS industry but believes that its vertical-specific solutions will remain relevant [54][58] - The management team is optimistic about the future, expecting overall revenue growth of 20%-50% in 2026 due to improved operational efficiency and reduced costs [70] Other Important Information - The company has optimized its client structure by reducing low-margin customers, which has positively impacted overall profitability [30][39] - The total assets of the group reached CNY 6.96 billion, with cash and cash equivalents at CNY 2.1 billion, indicating a solid financial position [32] Q&A Session Summary Question: Can the management team walk us through the AI business revenue and future outlook? - Management highlighted that AI-related revenue reached CNY 160 million, with various agent applications embedded into SaaS products, contributing to commercialization [42][45] Question: What are the challenges and opportunities for the SaaS industry in the face of AI? - Management noted that while AI impacts general SaaS tools, vertical-specific solutions remain essential due to the need for industry know-how [54][55] Question: Can the management elaborate on the overseas strategy and expected growth? - The company aims to provide a one-stop solution for Chinese merchants expanding internationally, with expectations for overseas business revenue to grow significantly [60][66]

Financial Data and Key Metrics Changes - In FY 2025, revenue and adjusted EBITDA increased by 10.8% year-on-year, with pro forma growth rates of 13.2% for revenue and 14.2% for adjusted EBITDA when including deconsolidated revenue and EBITDA [9][15] - The company achieved positive cash flow pre-financing of RMB 1 billion, with operating cash flow for the full year around RMB 3.4 billion, significantly improved from previous year [11][12] - The net debt to last quarter annualized adjusted EBITDA decreased from 6.8x at the end of 2024 to 5.8x at the end of 2025, with a further adjusted ratio of 4.8x when accounting for capital recycling [13][14] Business Line Data and Key Metrics Changes - The company recorded gross additional area utilization of around 23,000 square meters in 4Q 2025, with full-year gross move-in exceeding 86,000 square meters, the highest ever [6][7] - New bookings for the full year reached over 96,000 square meters, or over 300 MW, three times the level of the past three years, with a target of over 500 MW for 2026 [7][8] Market Data and Key Metrics Changes - The company is focusing on three new growth markets: Horinger in Inner Mongolia, Zhongwei in Ningxia Province, and Shaoguan in Guangdong Province, with over 400 megawatts of new orders and MOUs secured in these locations [8][41] - The demand for data centers is primarily driven by AI, with expectations that 60%-70% of new business will come from AI-related projects [7][8] Company Strategy and Development Direction - The company is building a 3-gigawatt pipeline in new growth markets to complement its existing powered land of 700 megawatts [5][6] - The strategy includes increasing cash reserves to over $2.8 billion to prepare for a new growth phase, supported by successful asset monetization [6][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in converting MOUs to contracts within two quarters, indicating a high certainty of order conversion [19] - The competitive landscape in new markets is characterized by high barriers to entry set by the government, which favors companies with strong track records and customer commitments [20][21] - The company anticipates that the demand trajectory in China will mirror that of the U.S., particularly as chip supply improves [70] Other Important Information - The company aims to complete an asset injection into its C-REIT in the second half of 2026, with selected assets larger than the seed asset for the IPO [12] - The company has raised $385 million through a partial sell-down of its stake in DayOne, with remaining stake valued at $2.2 billion [12] Q&A Session Summary Question: What is the timetable for converting MOUs to contracts and the associated risks? - Management indicated a high certainty of conversion within two quarters, emphasizing confidence in the process [19] Question: How is competition in new focus areas like Inner Mongolia and Shaoguan? - Management noted existing operators in these markets but emphasized high barriers set by the government, which positions the company favorably [20][21] Question: What are the trends in non-AI workloads? - Management stated that traditional cloud demand continues to grow but is increasingly associated with AI demand [26] Question: What is the customer concentration in new locations? - Management acknowledged a trend towards higher customer concentration among top players in the industry [56] Question: What is the expected delivery timeline for the 200 MW order? - Management expects an average delivery time of four quarters for the new orders [51] Question: How does the company view CapEx guidance in light of strong sales momentum? - Management believes the current CapEx guidance of RMB 9 billion is adequate and does not expect to revise it upward [66]

Eve Holding (NYSE:EVEX) Q4 2025 Earnings call March 17, 2026 08:00 AM ET Company ParticipantsEduardo Couto - CFOJohann Bordais - CEOLucio Aldworth - Director of Investor RelationsLuiz Valentini - CTOConference Call ParticipantsAndre Madrid - VP and Aerospace and Defense AnalystAndres Sheppard Slinger - Research AnalystAustin Moeller - Senior Aerospace and Defense Technology AnalystEllen Page - Equity AnalystMarcelo Motta - Research AnalystSamir Doshi - AnalystSavanthi Syth - Managing Director and Senior Equ ...